AlphAIAlphAI — Financial news for AI agents
prnewswire.comSEP 141 min read$CODX

SUMMARY NOTICE OF (I) PROPOSED SETTLEMENT; (II) MOTION FOR AN AWARD OF ATTORNEYS' FEES AND REIMBURSEMENT OF LITIGATION EXPENSES; AND (III) SETTLEMENT HEARING

Co-Diagnostics, Inc. and other defendants have agreed to a $6.5M settlement in a class action lawsuit. The suit involves investors who traded the company's stock or options between May 12, 2022, and August 11, 2022. A hearing to approve the settlement is scheduled for December 8, 2026. Class members must submit claims by January 6, 2027, to share in the settlement fund.

Original reporting
prnewswire.com
Published Sep 14, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CODX
Neutral
high confidence
Mentioned
$CODX
Relevance
4/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

Resolution of the lawsuit removes legal uncertainty but the settlement size is small relative to the company's valuation.

02

Market read

Primary relevance is to CODX shareholders; broader market impact is minimal.

03

What to watch

Potential for future litigation or regulatory scrutiny that could affect the company beyond this settlement.

Relevance 4/10Novelty 4/10Timing: hearing scheduled Dec 8 2026

Background

The notice informs class members of a settlement proposal in a securities class action covering purchases of Co‑Diagnostics stock and options in 2022.

Company-level read

Ticker impact

$CODXNeutralHigh confidence
Context

Co-Diagnostics announced a proposed $6.5 million settlement to resolve a class action lawsuit.

Expected impact

Minimal movement; possible short‑term uptick if investors view resolution positively.

Evidence & confidence

Small settlement size and lack of operational change suggest negligible effect on valuation.

Market effects

Sector

None; the legal settlement is specific to Co‑Diagnostics and does not affect the broader diagnostics sector.

Regional

Limited to U.S. investors holding CODX shares.

Global

None

Counterpoint

What could challenge this read

If the settlement resolves lingering litigation risk, a modest rally could occur despite the small amount.

Key entities

  • company
    Co‑Diagnostics, Inc.

    Defendant in the securities class action.

  • lead plaintiff
    Stadium Capital LLC

    Court‑appointed lead plaintiff representing the class.

Read at source← All news

Related articles

AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics, Inc. (CODX): Results of Operations and Financial Condition

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min